Metformin significantly reduced proinflammatory markers (IL-6, TNF-α, CRP) in the serum of type 2 diabetic patients and suppressed NF-κB levels in the context of diabetes and intestinal inflammation through AMPK-independent and -dependent processes [85,86]. The gene discussed is NFKB1; the disease is type 2 diabetes mellitus.